600 bayer

Saturday, November 20, 2021
07:00 a.m. - 08:00 a.m. JST (Japan Standard Time - UTC+9)

Industry Sponsored Session by Bayer Yakuhin, Ltd. and Nippon Kayaku Co., Ltd.

Strategies for treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

In recent years, the results of some phase III clinical trials for non-metastatic castration-resistant prostate cancer (nmCRPC) treatment have been reported, and the importance of its treatment and the choice of treatment have received renewed attention. In this lecture, after a detailed lecture on the disease concept and risk classification of nmCRPC, the optimal treatment of nmCRPC will be considered, focusing on the data of Darolutamide, androgen-receptor inhibitor. 

Chairman
Kazuhiro Suzuki
Department of Urology, Gunma University Graduate School of Program sent to Eric/Gerry, approved but with comment to include intro on Sex. Dysfuction relation. Medicine

Speaker
Naoya Masumori
Department of Urology, Sapporo Medical University School of Medicine 


Print